CN1602860A - Dripping pills of clemastine fumarate and its preparation method - Google Patents
Dripping pills of clemastine fumarate and its preparation method Download PDFInfo
- Publication number
- CN1602860A CN1602860A CNA2004100553379A CN200410055337A CN1602860A CN 1602860 A CN1602860 A CN 1602860A CN A2004100553379 A CNA2004100553379 A CN A2004100553379A CN 200410055337 A CN200410055337 A CN 200410055337A CN 1602860 A CN1602860 A CN 1602860A
- Authority
- CN
- China
- Prior art keywords
- clemastine fumarate
- coolant
- preparation
- polyethylene glycol
- dissolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims abstract description 17
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 title claims description 30
- 229960002689 clemastine fumarate Drugs 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title claims description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 239000002826 coolant Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 8
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- -1 liquid paraffin Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940080350 sodium stearate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000009748 deglutition Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960001582 fenfluramine Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000009747 swallowing Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention uses super micro shattering and drop pills producing the technology to produce fenfluramine drop pills, reaching the purposes such as increasing speed, and dissolution of disintegration, increasing the medicine stability, reducing the dose of auxiliary materials and decreasing cost, with rapid effect and convenient use. It can be buccal as well as deglutition, has remarkable conformity, and is especially suitable for children, older man, sicker in bed or with difficulty of swallowing.
Description
Technical field
The present invention relates to a kind of pharmaceutical product and preparation method thereof, specifically clemastine fumarate drop pill and preparation method thereof.
Background technology
Clemastine fumarate is H
1Receptor antagonist can suppress the permeability of blood capillary, can be antipruritic rapidly, still have cholinolytic and sedation.
Clemastine fumarate is oral to be absorbed rapidly through digestive tract, the onset in back 30 minutes of taking medicine, and blood drug level reached the peak in 2～5 hours, acted on sustainable 12 hours, and it is more to be distributed in internal organs such as liver, kidney, lung, spleen.t
1/2Be 21 hours, in liver, be metabolized to Dan Jihua, two methylate, or combine, mainly by draining in urine and the feces, can appear in the milk on a small quantity with metabolite and a small amount of original shape medicament forms with glucuronic acid.List marketing at present tablet, clinical allergic rhinitis, urticaria and other anaphylaxis dermatosis of being mainly used in only arranged.
The clemastine fumarate mildly bitter flavor, soluble,very slightly in water, its disintegration of tablet time is long, dissolution and dissolution rate are low, absorption difference, and bioavailability is low, the supplementary product consumption ratio is big, child, old people, bed patient and dysphagia patients are taken inconvenience, and compliance is poor, have influenced the performance of clemastine fumarate therapeutical effect.
The present invention makes the clemastine fumarate drop pill by using ultramicro communication technique and dropping pill formulation Technology exactly, thereby overcomes the above defective of clemastine fumarate sheet, and the therapeutical effect of clemastine fumarate is given full play to.
Summary of the invention
The clemastine fumarate drop pill of making by using ultramicro communication technique and dropping pill formulation Technology not only have disintegrate molten loose fast, dissolution and dissolution rate improve, steady quality, the pill volume is little, easy to carry and use, onset is rapid, compliance is good, be particularly suitable for the characteristics that child, old people, bed patient and dysphagia patients are taken, but also has working condition and production equipment is simple, production cost is low, compares the advantage that supplementary product consumption reduces with tablet, has demonstrated fully the new drug research exploitation spirit that people-oriented.
For achieving the above object, the present invention by the following technical solutions: the clemastine fumarate fine powder of 1 weight portion through micronizing is added in 5～30 weight portion molten matrix, fully mixing, dropping preparation method is condensed into ball in coolant, remove coolant, drying, promptly.
The chemical name of clemastine fumarate is [R-(R among the present invention
*, R
*)]-1-methyl-2-[2-[1-(4-chlorphenyl)-1-benzene ethyoxyl] ethyl]-pyrrolidine (E)-2-butylene diacid salt, molecular formula is C
21H
26CLNOC
4H
4O
4, molecular weight is 459.97, structural formula is
Substrate among the present invention includes but not limited to polyethylene glycol 6000, Macrogol 4000, polyethylene glycol 1500, cetomacrogol 1000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glycerol monostearate acid, insect wax etc.
Coolant among the present invention includes but not limited to dimethicone, liquid paraffin, vegetable oil, water, alcoholic solution etc.
Below through detecting to beneficial effect of the present invention as directed
One, detects index and method
1. disintegrate (molten loosing) time limit: check according to inspection technique disintegration (two appendix XA of Chinese Pharmacopoeia version in 2000).
2. dissolution rate: sample thief, according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2000), [get citric acid-hydrate 1.0g with Chinese holly edge acid buffer (pH4.0), add water 1000ml and make dissolving, hydro-oxidation sodium solution (3 → 10) 22.0ml and hydrochloric acid 8.8ml, add the water mixing, make the solution of 2000ml, regulate pH value to 4.0, promptly] 500ml is a solution, rotating speed is that per minute 50 changes, and operation in accordance with the law is through 10,20,30, in the time of 40 minutes, get solution 50ml, get reference substance solution (it is an amount of to get the clemastine fumarate reference substance, and solubilizer is diluted to the concentration near need testing solution) 50ml and solvent 50ml simultaneously, put in the separatory funnel respectively.Each methylate orange solution (is got methyl orange indicator solution 20ml, thin up is to 100ml) 10ml, chloroform 20ml, jolting 10 minutes, tell chloroform layer, filter, get subsequent filtrate respectively, according to spectrophotography (two appendix IV of Chinese Pharmacopoeia version in 2000 B), wavelength place at 420nm measures trap, calculates stripping quantity.
Two, commercially available clemastine fumarate sheet testing result
1. disintegration time: 59 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 31.2 41.3 61.4 72.5
Three, example 1 sample detection result
1. the molten diffusing time: 3 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 63.6 98.4 97.3 99.6
Four, example 2 sample detection results
1. the molten diffusing time: 3 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 58.9 96.7 99.0 99.8
Five, example 3 sample detection results
1. the molten diffusing time: 3 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 67.3 98.9 97.2 98.6
Six, example 4 sample detection results
1. the molten diffusing time: 5 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 56.4 92.3 99.5 98.0
Seven, example 5 sample detection results
1. the molten diffusing time: 6 minutes
2. dissolution rate:
Time (minute) 10 20 30 40
Dissolution (%) 61.4 94.6 98.7 95.2
Eight, example 6 sample detection results
1. the molten diffusing time: 8 minutes
2. dissolution rate
Time (minute) 10 20 30 40
Dissolution (%) 52.3 93.4 98.6 96.5
The specific embodiment
One, example 1
Prescription:
Clemastine fumarate 1.34g
Polyethylene glycol 6000 20g
Make 1000
Method for making: the clemastine fumarate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused polyethylene glycol 6000 substrate, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Two, example 2
Prescription:
Clemastine fumarate 1.34g
Macrogol 4000 20g
Make 1000
Method for making: the clemastine fumarate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused Macrogol 4000 substrate, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Three, example 3
Prescription:
Clemastine fumarate 1.34g
Polyethylene glycol 6000 10g
Macrogol 4000 10g
Make 1000
Method for making: the clemastine fumarate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in fused Macrogol 4000 and the polyethylene glycol 6000 mixed-matrix, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Four, example 4
Prescription:
Clemastine fumarate 1.34g
Glyceryl monostearate 20g
Make 1000
Method for making: the clemastine fumarate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused glyceryl monostearate substrate, and mixing is a coolant with the frozen water, the dropping preparation method pill, and drying, promptly.
Five, example 5
Prescription:
Clemastine fumarate 1.34g
Polyethylene glycol 6000 15g
Poloxamer 5g
Make 1000
Method for making: the clemastine fumarate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in fused polyethylene glycol 6000 and the poloxamer mixed-matrix, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Six, example 6
Prescription:
Clemastine fumarate 1.34g
Glyceryl monostearate 20g
Poloxamer 1g
Make 1000
Method for making: get the mixing fine powders that clemastine fumarate and poloxamer cross 200 mesh sieves through micronizing and be added in the fused glyceryl monostearate substrate, mixing is a coolant with the frozen water, the dropping preparation method pill, and drying, promptly.
Claims (4)
1. clemastine fumarate drop pill and preparation method thereof is characterized in that: the clemastine fumarate fine powder of 1 weight portion through micronizing is added in 5～30 weight portion molten matrix, fully mixing, dropping preparation method is condensed into ball in coolant, remove coolant, drying, promptly.
2. the chemical name of the described clemastine fumarate of claim 1 is [R-(R
*, R
*)]-1-methyl-2-[2-[1-(4-chlorphenyl)-1-benzene ethyoxyl] ethyl]-pyrrolidine (E)-2-butylene diacid salt, structural formula is
, molecular formula is C
21H
26CLNOC
4H
4O
4, molecular weight is 459.97.
3. the described substrate of claim 1 includes but not limited to polyethylene glycol 6000, Macrogol 4000, polyethylene glycol 1500, cetomacrogol 1000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glycerol monostearate acid, insect wax etc.
4. the described coolant of claim 1 includes but not limited to dimethicone, liquid paraffin, vegetable oil, water, alcoholic solution etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100553379A CN1602860A (en) | 2004-08-23 | 2004-08-23 | Dripping pills of clemastine fumarate and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100553379A CN1602860A (en) | 2004-08-23 | 2004-08-23 | Dripping pills of clemastine fumarate and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1602860A true CN1602860A (en) | 2005-04-06 |
Family
ID=34666169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100553379A Pending CN1602860A (en) | 2004-08-23 | 2004-08-23 | Dripping pills of clemastine fumarate and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1602860A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102816101A (en) * | 2012-08-21 | 2012-12-12 | 江苏恒祥化工有限责任公司 | Synthesis method of (S)-N-methyl-2 chloro-ethyl-pyrrolidine |
| CN111920805A (en) * | 2020-08-14 | 2020-11-13 | 济南市儿童医院 | Application of clemastine fumarate in preparation of methicillin-resistant staphylococcus aureus |
-
2004
- 2004-08-23 CN CNA2004100553379A patent/CN1602860A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102816101A (en) * | 2012-08-21 | 2012-12-12 | 江苏恒祥化工有限责任公司 | Synthesis method of (S)-N-methyl-2 chloro-ethyl-pyrrolidine |
| CN111920805A (en) * | 2020-08-14 | 2020-11-13 | 济南市儿童医院 | Application of clemastine fumarate in preparation of methicillin-resistant staphylococcus aureus |
| CN111920805B (en) * | 2020-08-14 | 2021-11-19 | 山东省妇幼保健院 | Application of clemastine fumarate in preparation of methicillin-resistant staphylococcus aureus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1602860A (en) | Dripping pills of clemastine fumarate and its preparation method | |
| CN1582908A (en) | Tramadol hydrochloride drops and their preparation | |
| CN1602848A (en) | Ambroxol hydrochloride drop pills and its preparation method | |
| CN1562001A (en) | Carbazochrome sodium sulfoate dripping pill and its preparing method | |
| CN1543935A (en) | Tulobuterol hydrochloride guttate pill and method for preparing the same | |
| CN1602868A (en) | Dripping pills of ketotifen fumarate and its preparation method | |
| CN1528321A (en) | Rhizoma gastrodiae extract drop pill and preparing method thereof | |
| CN1528287A (en) | Herba lysionoti extract drop pill and preparing method thereof | |
| CN1546022A (en) | Dripping pills of luteanine hydrochloride and its preparation | |
| CN1526393A (en) | Hydralazine hydrochloride guttate pills and the prepn | |
| CN1528298A (en) | Isocarboxazid drop pill and preparing method thereof | |
| CN1543967A (en) | Benproperine phosphate dripping pills and preparation | |
| CN1569004A (en) | Dripping pills of nefopam hydrochloride and its preparation method | |
| CN1602870A (en) | Dripping pills of bucinnazine hydrochloride and its preparation | |
| CN1568947A (en) | Bromhexine Hydrochloride drop pills and preparation method thereof | |
| CN1602845A (en) | Fenfluramine hydrochloride drop pills and its preparation method | |
| CN1582939A (en) | Dioxyimipramine hydrochloride drops and their preparation | |
| CN1568987A (en) | Dripping pills of paroxetine hydrochloride and its preparation method | |
| CN1528299A (en) | Bisacodyl drop pill and preparing method thereof | |
| CN1528301A (en) | Nicorandic drop pill and preparing method thereof | |
| CN1543961A (en) | Oxazepam dripping pills and preparation thereof | |
| CN1582943A (en) | Clomipramine hydrochloride drops and their preparation | |
| CN1568948A (en) | Venlafaxine hydrochloride drop pills and preparation method thereof | |
| CN1526385A (en) | Ditropan hydrochloride dripping pills and the prepn process | |
| CN1493288A (en) | Hanfangchin A drip pill and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |